Oct 20 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO
* Aurinia Pharmaceuticals Inc - plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease
* Aurinia Pharmaceuticals - plans to evaluate proprietary nanomicellar voclosporin ophthalmic solution for treatment of keratoconjunctivitis sicca/ DES
* Aurinia Pharmaceuticals - a phase II proof of concept clinical trial for voclosporin in FSGS and MCD patients will be initiated in first half of 2018